Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Ther Bull. 2013 Oct;51(10):114-7. doi: 10.1136/dtb.2013.10.0208.

What place for lisdexamfetamine in children and adolescents with ADHD?

[No authors listed]

Abstract

Attention deficit hyperactivity disorder (ADHD) is the commonest behavioural disorder in the UK, affecting 2-5% of school-aged children and young people.(1) Guidelines from the National Institute for Health and Care Excellence (NICE) state that medication is not indicated as first-line treatment for school-age children and young people with ADHD, but should be reserved for those with severe symptoms and impairment, or those with moderate levels of impairment who have refused non-drug interventions, or those whose symptoms have not responded sufficiently to parent-training/education programmes or group psychological treatment.(2) Current drug options include methylphenidate (first-line), atomoxetine (first- or second-line) or dexamfetamine (second- or third-line).(2) Lisdexamfetamine (Elvanse-Shire Pharmaceuticals) is a prodrug of dexamfetamine, licensed as part of a comprehensive treatment programme for ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.(3,4) Here we review the place of lisdexamfetamine in the management of ADHD in children and adolescents.

PMID:
24113146
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk